tirzepatide from lilly direct releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Zepbound direct

With its dual mechanism of action, it mimics natural incretin hormones to regulate blood sugar levels and reduce food intake, providing a comprehensive approach to managing these chronic conditions

A peptide is a tool, not a full plan, so these drawbacks are easier to manage when peptide therapy is paired with an approach that addresses the root causes behind the weight

Researchers who begin with microdosing approaches may see slower initial progress but better tolerance

Tirzepatide Regulatory Status in Canada Health Canada Approval Status (Mounjaro and Zepbound) Tirzepatide is the active ingredient in two Eli Lilly Canada products authorized by Health Canada: Mounjaro (authorized 2022 to improve glycemic control in adults with type 2 diabetes) and Zepbound (authorized May 13, 2025 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity)

Cureus, 15 (1), e33475

The medication is typically injected once a week, and patients are advised to rotate injection sites to decrease the likelihood of tissue irritation